ReviewMycopathologia2014
Fungal culture and sensitisation in asthma, cystic fibrosis and chronic obstructive pulmonary disorder: what does it tell us?
Review in Mycopathologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- A systematic review of outdoor airborne fungal spore seasonality across Europe and the implications for health.The Science of the total environment · 2022Pooled it
- Coinfection of Pulmonary Hydatid Cyst and Aspergilloma: Case Report and Systematic Review.Mycopathologia · 2016Pooled it
- Clinical characteristics and risk factors analysis of allergic bronchopulmonary aspergillosis combined with bronchiectasis.Frontiers in medicine · 2025Article
- Correlation ofInternational journal of chronic obstructive pulmonary disease · 2025Article
- The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review.Central-European journal of immunology · 2024Review
- Sensitisation to recombinantThe European respiratory journal · 2023Article
- Article
- The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives.Microorganisms · 2022Review
- Patient-Centered Discussion on End-of-Life Care for Patients with Advanced COPD.Medicina (Kaunas, Lithuania) · 2022Review
- Allergic fungal airways disease (AFAD): an under-recognised asthma endotype.Mycopathologia · 2021Review
- Article
- Aspergillus fumigatus Detection and Risk Factors in Patients with COPD-Bronchiectasis Overlap.International journal of molecular sciences · 2018Article
- Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.Mycopathologia · 2018Review
- Fungi in Bronchiectasis: A Concise Review.International journal of molecular sciences · 2018Review
- Characterizing the Human Mycobiota: A Comparison of Small Subunit rRNA, ITS1, ITS2, and Large Subunit rRNA Genomic Targets.Frontiers in microbiology · 2018Article
- Article
- Advances against aspergillosis: biology, host response, diagnosis and treatment.Mycopathologia · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collectively asthma, chronic obstructive pulmonary disorder (COPD) and cystic fibrosis (CF) are very common, important causes of disease and ill health. Filamentous fungal colonisation of the airways can occur in all three disease groups, although the clinical relevance is unclear. Allergic bronchopulmonary aspergillosis (ABPA) is a well-recognised severe complication of airway colonisation associated primarily with Aspergillus fumigatus. Fungal colonisation may have a deleterious effect without fulfilling all the diagnostic criteria of ABPA; however, a lack of standardisation in processing respiratory samples hampers comparisons. Whilst mycology laboratory accreditation programs are common, most countries have no national standard guidelines for processing respiratory samples. Fungal recovery from sputum in CF, asthma and COPD can be around 40, 54 and 49%, respectively. Isolation of fungi from sputum has been associated with reduced lung function in asthma and CF, although no such associations have been found in COPD. It is unclear whether fungal colonisation contributes to lower lung function or is a marker of more severe lung disease and aggressive therapy. Fungal sensitisation may contribute to the persistence of active respiratory symptoms; however, the exact prevalence is unclear. Sensitisation to A. fumigatus has been associated with reduced lung function in asthma, COPD and CF. It has suggested that both skin prick tests and specific IgE measurement by the ImmunoCAP system should be used in diagnoses of allergy, due to discordance in test results; however, there is currently no widely adopted consensus as to which fungi to test for.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.